Monday, July 14, 2008 8:33:40 AM
Monday July 14, 8:21 am ET
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR - News) today announced its intention to fully support the Pharmaceutical Research and Manufacturers of America’s (PhRMA) updated and enhanced Code on Interactions with Healthcare Professionals (PhRMA Code). The purpose of the revised PhRMA Code includes addressing interactions with respect to marketed pharmaceutical products and related pre-launch activities, and the industry’s relationships with clinical investigators and others as they relate to the clinical research process.
“Sepracor has always been committed to responsible and ethical interactions with healthcare professionals,” said Adrian Adams, President and Chief Executive Officer of Sepracor. “This new PhRMA Code serves to underscore the importance of maintaining an appropriate, two-way, educational or informational communication between healthcare professionals and pharmaceutical industry representatives. During the next six months, we intend to update our policies and procedures to ensure compliance with not only the letter, but the spirit, of the standards set forth in the new PhRMA Code.”
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM